Skip to main content
Equibles
KZIA logo

KZIA · Kazia Therapeutics Ltd

Track KZIA — free

Use KZIA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KZIA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.19 +0.18 (+1.63%) At close · Sep 11
Rebalance outlook locked
Market Cap
$127.87M
Shares
11.43M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.19 Open$11.10 Day$10.83–11.43 52W close$5.00–16.90 Avg vol 30d292K Short int906K · 7.9% float · 2.9d Short vol45% DataApr 2025–Sep 2026

Raw chart and full-history price indicators begin at the captured split on Apr 17, 2025; bars on opposite sides are not compared.

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+33.5%
Trailing year
Short interest
7.9%
Latest settlement · 2.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +5%
above
Price vs 50-day avg −15%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 52%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −15%
trailing
6-month return +50%
trailing
YTD return +62%
this year
Relative strength +32%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $13 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+52% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.93% of float · ▲ +62.0% MoM · 2.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
35 holders — near 3-yr high, broad support
Squeeze score 58
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 126%
annualized · 1-yr
Max drawdown −68%
past year
ATR 10.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+5% Bullish
Price vs 50-day avg
−15% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
52% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $13 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+52% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.93% of float · ▲ +62.0% MoM · 2.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
35 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5 Now $11 · 52% Range high $17
vs 200-day avg +5% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KZIA
Kazia Therapeutics Ltd
this stock
$127.87M +62.4% — — 7.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
35
% held
35.3%
Net QoQ
+2.3M sh
Top holder
Boxer Capital Management,…
Held Float
View
Held by Funds
Fund positions
3
View
Short & Settlement
Short Interest Rising
Shares short
905.8K
Days to cover
2.9d
Change
+346.7K sh
View
Short Volume
Short vol %
45%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
70
Value
$925
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
41.6%
Week of
Aug 3, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 1, 2026
This year
15
View
Exempt Offerings
Offering
$55.3M
Filed
Dec 18, 2025
View

Performance

Raw-price comparisons begin at the captured split on Apr 17, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
KZIA -8.0% -15.3% +49.6% -18.7% +62.4%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -6.8% -13.5% +31.8% -18.4% +50.3%
Key facts CIK 1075880 CUSIP 48669G303 13F (30d) 25 filings 25 filers Visit website Investor relations